The three-day initial public offering (IPO) of Delhi-based drugmaker Mankind Pharma will open for public subscription on April 25 and close on April 27, according to the Red Herring Prospectus (RHP).
The three-day initial public offering (IPO) of Delhi-based drugmaker Mankind Pharma will open for public subscription on April 25 and close on April 27, according to the Red Herring Prospectus (RHP).
The tender for anchor investors will open on April 24th. The shares will be credited on May 8th and the stock is expected to be listed on both the NSE and BSE on May 9th.
The tender for anchor investors will open on April 24th. The shares will be credited on May 8th and the stock is expected to be listed on both the NSE and BSE on May 9th.
The price range for the IPO has yet to be announced.
The price range for the IPO has yet to be announced.
The Company’s IPO is entirely an Offer for Sale (OFS) of 40,058,844 shares from Promoters and other existing shareholders.
The Company’s IPO is entirely an Offer for Sale (OFS) of 40,058,844 shares from Promoters and other existing shareholders.
Those selling shares in OFS are promoters Ramesh Juneja, Rajeev Juneja and Sheetal Arora. Cairnhill CIPEF, Cairnhill CGPE, Beige Limited and Link Investment Trust will also participate in the OFS.
Those selling shares in OFS are promoters Ramesh Juneja, Rajeev Juneja and Sheetal Arora. Cairnhill CIPEF, Cairnhill CGPE, Beige Limited and Link Investment Trust will also participate in the OFS.
As the IPO is fully an OFS, the company will not receive any net proceeds from the offering and all net proceeds will go to the selling shareholders.
As the IPO is fully an OFS, the company will not receive any net proceeds from the offering and all net proceeds will go to the selling shareholders.
Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India and JP Morgan India are the underwriters of the offering.
Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India and JP Morgan India are the underwriters of the offering.
Mankind Pharma is engaged in the development, manufacturing and marketing of a wide range of pharmaceutical formulations in various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Mankind Pharma is engaged in the development, manufacturing and marketing of a wide range of pharmaceutical formulations in various acute and chronic therapeutic areas, as well as several consumer healthcare products.
It has established several differentiated brands in the categories of condoms, pregnancy detection, emergency contraception, antacid powders, vitamin and mineral supplements, and anti-acne supplements.
It has established several differentiated brands in the categories of condoms, pregnancy detection, emergency contraception, antacid powders, vitamin and mineral supplements, and anti-acne supplements.
It has a pan-Indian marketing presence and operates 25 manufacturing facilities across the country.
It has a pan-Indian marketing presence and operates 25 manufacturing facilities across the country.
As of December last year, the company had a team of more than 600 scientists and a dedicated in-house R&D center with four units at IMT Manesar, Gurugram (Haryana) and Thane (Maharashtra).
As of December last year, the company had a team of more than 600 scientists and a dedicated in-house R&D center with four units at IMT Manesar, Gurugram (Haryana) and Thane (Maharashtra).
Comments are closed.